Prehabilitation using adapted physical activity for multiple myeloma patients before autologous stem cell transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional, single-center program compares a structured adapted physical activity (APA) prehabilitation program to usual care (no intervention) for patients with multiple myeloma who are eligible for autologous stem cell transplantation. Outcomes include validated questionnaires on quality of life, fatigue, and physical activity, and feasibility measures focused on adherence (completed vs planned sessions) and attrition. The protocol excludes patients with medical contraindications to exercise, significant neuropathy, recent other cancers, or legal/psychosocial barriers to participation. The program is delivered at Centre Hospitalier Henri Duffaut in Avignon and requires a medical prescription for APA.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years old.
* CML patient in chronic phase, eligible for oral therapy.
* Diagnosis of multiple myeloma.
* Patient eligible for autologous stem cell transplantation.
* Patient capable to read, understand and complete a questionnaire in french.
* WHO less than or equal to 2.
* Patient affiliated with french social security.
* Patient with a medical prescription for APA.

Exclusion Criteria:

* Patient with previous cancer within the previous 3 years (except basal cell and squamous cell skin cancers, carcinomas in situ of any type that have been previously resected, and stable prostate or breast cancers more than 3 years old and undergoing adjuvant hormone therapy).
* Medical contraindications to APA (heart failure, angina, unbalanced hypertension, bone metastases, severe osteoporosis, etc.)
* Sensory or motor neuropathy.
* Patient deprived of liberty, under guardianship or curatorship.
* Patient considered socially or psychologically unfit to be enrolled in a study.

Where it's running

• Centre Hospitalier d'Avignon, Hôpital Henri Duffaut
  Avignon, France Recruiting

Study contacts

• Study coordinator: Marilyne Grinand, PhD
• Email: grinand.marilyne@ch-avignon.fr
• Phone: (+33)432759392

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 6MW5311 in adults with relapsed or refractory blood cancers

  This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.

  Recruiting Phase 1 Mabwell (Shanghai) Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT07914556

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma

  In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.

  Recruiting Phase 4 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07907211

• Exercise phenotyping before chemotherapy in newly diagnosed multiple myeloma

  This observational study tests whether some newly diagnosed multiple myeloma patients with normal resting heart function already show limited exercise capacity, and whether that limitation relates to subtle heart tissue changes and future heart-related outcomes.

  Recruiting Technical University of Munich · Munich, Bavaria · NCT07851493

• SMS text check-ins to track symptoms for people with plasma cell disorders

  This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07850284

• Cevostamab with Pomalidomide and Dexamethasone after BCMA-directed CAR T therapy in multiple myeloma

  This study tests if Cevostamab combined with pomalidomide and dexamethasone can help people with multiple myeloma who have already had CAR T therapy and several prior treatments.

  Recruiting at 5 sites Phase 2 Hoffmann-La Roche · Nuremberg, Bavaria and 4 other locations · NCT07825064

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.